Discovery of an ape virus in an Indonesian rodent species

The gibbon ape leukemia virus (GALV) is a medically important tool in cancer therapies. GALV is a retrovirus pathogenic to its host species, the southeast Asian lar gibbon (Hylobates lar) and thought to have originated from a cross-species transmission and may not originally be a primate virus at all. An international research team screened a wide range of rodents from southeast Asia for GALV-like sequences. The discovery of a new GALV in the grassland melomys (Melomys burtoni) from Indonesian New Guinea supports the hypothesis that this host species, and potentially related rodent lineages in Australia and Papua New Guinea, may have played a key role in the spread of GALV-like viruses.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Silvia Schenone Protein kinases have emerged as crucial targets for cancer therapy over the last decades. Since 2001, 40 and 39 kinase inhibitors have been approved by FDA and EMA, respectively, and the majority are antineoplastic drugs. Morevoer, many candidates are currently in clinical trials. We previously reported a small library of 4-aminoimidazole and 2-aminothiazole derivatives active as Src family kinase (SFK) inhibitors. Starting from these results, we decided to perform an optimization study applying a mix and match strategy to identify a more potent generation of 4-aminoimidazoles. Firstly, a computationa...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Publication date: 15 January 2019Source: Journal of Molecular Structure, Volume 1176Author(s): Srinivasulu Cherukupalli, Balakumar Chandrasekaran, Rajeshwar Reddy Aleti, Nisar Sayyad, Girish A. Hampannavar, Srinivas Reddy Merugu, Harikrishna Reddy Rachamalla, Rajkumar Banerjee, Rajshekhar KarpoormathAbstractThe cyclin-dependent kinases (CDKs) play a crucial role in cell cycle progression and are validated targets of cancer therapy. Pyrazolopyrimidines are versatile scaffolds, which have been exploited for developing potential anticancer agents. We herein report the synthesis and in vitro CDK2/cyclin E kinase inhibitor...
Source: Journal of Molecular Structure - Category: Molecular Biology Source Type: research
Abstract Sorcin (Soluble resistance related calcium binding protein) is a small soluble penta EF family (PEF) of calcium (Ca2+) binding protein (22,000 Da). It has been reported to play crucial roles in the regulation of calcium homeostasis, apoptosis, vesicle trafficking, cancer development, and multidrug resistance (MDR). Overexpression of sorcin has been reported to be associated with different cancers such as breast cancer, colorectal cancer, gastric cancer, leukemia, lung cancer, nasopharyngeal cancer, ovarian cancer, etc. Essentially, expression of sorcin has been found to be elevated in cancer cells as comp...
Source: Translational Oncology - Category: Cancer & Oncology Authors: Tags: Transl Oncol Source Type: research
In this study, we screened 114 FDA-approved anti-cancer drugs for their effects on angiogenesis in the zebrafish. Among those with positive effects, we chose to focus on Ponatinib (AP24534; Iclusig®) for further investigation. Ponatinib is an inhibitor of the tyrosine kinase BCR-ABL in chronic myeloid leukemia (CML), and its clinical trial has been approved by FDA for the treatment of the disease. In recent clinical trials, however, some side effects have been reported for Ponatinib, mostly on blood vessel disorders, raising the possibility that this drug may influence angiogenesis. In this study, we demonstrated that ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
The cutting-edge treatment is expensive but could potentially cure children with advanced leukaemia.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news
LOS ANGELES– Stand Up To Cancer (SU2C), a division of the Entertainment Industry Foundation (EIF), is proud to announce that the Hollywood community is rallying together yet again to support the sixth biennial televised fundraising special. CBS will donate one hour of commercial-free primetime to broadcast the event on Friday, Sept. 7  from 8:00 – 9:00 PM ET/PT (7:00 – 8:00 PM CT). Mahershala Ali, Kathy Bates, Katie Couric, Jennifer Garner, Tony Hale, Marg Helgenberger, Ed Helms, Ken Jeong, Marlee Matlin, Matthew McConaughey, Maria Menounos, Jillian Michaels, Trevor Noah, Dak Prescott, Italia Ricci, ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health Only CBS Stand Up To Cancer Source Type: news
This article provides an update of data that help inform clinicians of the role anthracyclines should play in adjuvant breast cancer therapy. Two recently reported large randomized trials-the Anthracycline in Early Breast Cancer and Western German Study Plan B studies-compared a taxane and cyclophosphamide regimen with an anthracycline, taxane, and cyclophosphamide regimen. Although the studies had conflicting results, together these studies suggest that the benefit of adjuvant anthracycline therapy over a nonanthracycline taxane-containing regimen is modest at best and may be primarily seen in patients with especially hig...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
ConclusionsHK2 is a highly upregulated enzyme in cancer and in T cells. The requirement for HK2 in various cancer models has been described previously. Our finding that T cells are able to withstand the loss of HK2 indicates that HK2 may be a promising candidate for cancer therapy. Furthermore, we identify several other potential metabolic targets in T-ALL leukemia that could spare T cell function.
Source: Cancer and Metabolism - Category: Cancer & Oncology Source Type: research
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
In this study we characterized mechanisms behind this niche-mediated chemoresistance.
Source: Experimental Hematology - Category: Hematology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Indonesia Health | Leukemia | Papua New Guinea Health | Science